Search

everythinglearnresearchcommunity

for

Search:↓

Men's hair loss is caused by hormones and genes, and can be treated with medication and surgery, while graying is due to aging and has no prevention except dyeing.

The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.

A male with aromatase deficiency improved bone health with estradiol treatment.

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

Losing eyelashes or eyebrows can be a sign of many different health problems and needs a careful approach to treat effectively.

The conclusion is that exogen is a unique hair cycle phase and the new sampling method specifically targets this stage, which may help in future hair loss research.

Stress and alcohol affect brain chemicals differently in rats, mice, and humans, influenced by genetic differences.

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Bald men may have higher heart disease risk.

Cellular senescence has both cancer-blocking and cancer-promoting effects, and targeting senescent cells may improve health and lifespan.

The document concludes that recognizing oral lesions is important for diagnosing syphilis.

People with psoriasis are more likely to have Metabolic Syndrome than those without psoriasis.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.

Activating NRF2 might help treat hair disorders by improving antioxidant defenses.

Exposure to Corexit dispersants during the oil spill cleanup was linked to increased respiratory and eye irritation symptoms in workers.

Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.

A team approach is crucial for managing PCOS, with dermatologists playing a key role.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

Minoxidil use during pregnancy may cause fetal harm.

Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

Lipocalin-2 levels are higher in women with PCOS and may indicate insulin resistance.

The document concludes that menopause should be seen as a natural part of aging and managed with personalized care and informed choices.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.